Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026)
Valneva SE (VALN) posted quarterly Total Non-Current Liabilities of $228.8 million for Q1 2026, little changed year-on-year from $228.5 million in Q1 2025, and up 0.88% on a QoQ basis from $226.8 million in Q4 2025.
Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Total Non-Current Liabilities for 7 consecutive years, with $228.8 million the latest figure, recorded in Q1 2026.
- Quarterly Total Non-Current Liabilities changed 0.15% year-over-year to $228.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $228.8 million (changed 0.15% YoY) and the FY2025 annual result came in at $226.8 million, down 2.38% from the prior year.
- Total Non-Current Liabilities rose to $228.8 million in Q1 2026 per VALN's latest filing, from $226.8 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for VALN reached as high as $302.8 million in Q1 2022 and fell as low as $126.1 million in Q2 2023.
- A 5-year average of $200.4 million and a median of $216.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 55.31% — and 2024, when it surged 78.49%.
- Year by year, Total Non-Current Liabilities stood at $141.3 million in 2022, then surged by 39.3% to $196.8 million in 2023, then rose by 18.07% to $232.4 million in 2024, then retreated by 2.38% to $226.8 million in 2025, then grew by 0.88% to $228.8 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $228.8 million, $226.8 million, and $167.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 228.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 228.84 Mn |
| Dec 31, 2025 | 226.83 Mn |
| Sep 30, 2025 | 167.59 Mn |
| Jun 30, 2025 | 182.68 Mn |
| Mar 31, 2025 | 228.49 Mn |
| Dec 31, 2024 | 232.37 Mn |
| Sep 30, 2024 | 216.20 Mn |
| Jun 30, 2024 | 225.09 Mn |
| Mar 31, 2024 | 224.76 Mn |
| Dec 31, 2023 | 196.81 Mn |
| Sep 30, 2023 | 164.85 Mn |
| Jun 30, 2023 | 126.11 Mn |
| Mar 31, 2023 | 138.78 Mn |
| Dec 31, 2022 | 141.28 Mn |
| Sep 30, 2022 | 180.81 Mn |
| Jun 30, 2022 | 222.72 Mn |
| Mar 31, 2022 | 302.75 Mn |
| Dec 31, 2021 | 316.11 Mn |
| Dec 31, 2020 | 222.89 Mn |